Genentech, Chiron Settle Herceptin Patent Dispute
Biotech companies Genentech, Inc. and Chiron have quietly settled the remaining patent disputes in a $300 million lawsuit over Genentech's metastatic breast cancer drug, Herceptin (Trastuzumab)....To view the full article, register now.
Already a subscriber? Click here to view full article